The effectiveness of Merck’s (MRK) cholesterol lowering drug Zetia has been put to question following the release of data from a ... of the study may hamper the sales potential of Merck’s cholesterol drugs further. This is the third time in the last two years that negative results have lowered ... recommendation on Merck. Zacks Investment Research (MRK) Merck Cholesterol Drug Data Sees Setback

Isis Pharmaceuticals (ISIS) says that its experimental cholesterol drug mipomersen hit its primary endpoint in a late-stage trial, ... percent among patients genetically inclined to develop high cholesterol. And some patients demonstrated a reduction of 70 to 80 percent. ... over 400 while guidelines call for a level under 100. The drug is given by injection once a week. Another late-stage trial examines ...

  Bad news continues to buffet the once-blockbuster cholesterol drug ezetimibe, which is sold under the brand name Zetia. ... and exercise don't reduce a person's cholesterol enough. But sometimes even statins fall short and people need additional treatment ... major blow to ezetimibe. They come on the heels of reports that the drug may raise the risk of cancer and a decision by its manufacturers ...

A new study raises more questions about ezetimibe (Zetia), a drug used by millions of Americans in tandem with statins to lower LDL, or "bad," cholesterol. The trial, known as ARBITER-6 HALTS, ... than extended-release niacin (Niaspan), which raises HDL, or "good," cholesterol levels, in reducing plaque build-up in the arteries.

... enzymes in the highly reducing iterative polyketide synthases found in filamentous fungi. This enzyme is responsible for producing the cholesterol-lowering compound lovastatin. Lovastatin is a blockbuster drug used for lowering cholesterol in those with hypercholesterolemia, and thus helps to prevent cardiovascular disease.

... company filed for a patent on the slightly modified form of the drug and bought back the capsules that pharmacies still had on their shelves. ... wrongdoing. Also last year, the FDA approved a new Abbott drug called Trilipix, which is similar to TriCor but which is approved for use in combination with statins, a popular class of cholesterol drug. Now Abbott is busy trying to get patients to switch ...

... one of the sleaziest and most blatantly self-serving yet. Over the last few years, drug-makers have embraced a startlingly simple tactic ... return, we'll give you a share of our profits on the drug. So common have these deals become lately that they've been given a name: pay-for-delay ... 90 percent cheaper than the name brands. For instance, the cholesterol drug Zocor costs $164 a month ...

... November 16, 2009 A widely prescribed and expensive cholesterol drug is not as effective as niacin, a cheap vitamin, ... to raise questions about the effectiveness of Zetia and its sister drug, Vytorin, highly profitable pharmaceuticals made ... brand name for ezetimibe, uses a different mechanism. It blocks the absorption of cholesterol from food in the intestines. It has been shown by Merck to lower ...

... dramatic lowering of LDL (bad) cholesterol. In earlier studies with green monkeys, the drug had a stronger effect on ... ; Lanford said in his email. “I do not suspect that this will be a limitation of this drug, but human clinical trial data are needed ... nucleotides, the building blocks of DNA and RNA. The drug is actually an antisense nucleotide, meaning that it is assembled in a way that makes ...

... a statement stating that taking Lexiva could raise your cholesterol and triglyceride levels, placing you at risk for developing heart disease in the future. Lexiva, a drug manufactured by Glaxo Smith Kline, is used in combination with ... stop taking Lexiva because of this. However, if you are taking the drug, make sure you are getting your cholesterol and triglyceride levels checked at regular ...